MetaVia Inc. 8-K

What Happened

• On July 9, 2026, MetaVia Inc. (MTVA) announced via a press release (filed as Exhibit 99.1) that all enrolled active patients in Part 3 of its Phase 1 clinical trial of DA-1726 for obesity have successfully completed dose titration and are now receiving their highest target doses. The two study cohorts are receiving target doses of 48 mg and 64 mg. The company reported that topline data from Part 3 remains on track for release in the fourth quarter of 2026.
• The 8-K includes the Regulation FD disclosure and standard forward-looking statement cautions noting actual results may differ from expectations.

Key Details

• Filing date: July 9, 2026 (press release attached as Exhibit 99.1).
• Trial stage: Part 3 of Phase 1 for DA-1726 (obesity treatment).
• Doses: Patients now on highest target doses of 48 mg and 64 mg in the two cohorts.
• Data timing: Topline readout planned for Q4 2026.

Why It Matters

• This is a clinical-development milestone showing Part 3 enrollment/titration is complete and the study has progressed to maintenance of target dosing—an important step before reporting topline efficacy and safety results.
• The announced Q4 2026 topline timeline gives investors a near-term catalyst to watch; results could affect the company’s clinical valuation and investor expectations. The company’s filing also reiterates standard forward-looking statement risks, so timing and outcomes remain subject to change.